Progress in two major areas over the past 10 years has contributed to increasing optimism for improved understanding of pediatric disease and its pharmacologic management both now and in the future. First, a series of legislative changes targeted improved drug therapy in children of all ages. In 1994, the Food and Drug Administration (FDA) Pediatric Rule essentially provided an avenue for manufacturers to insert information pertaining to the clinical pharmacology and therapeutic use of drugs in pediatric patients into approved product labeling. The FDA Modernization Act (FDAMA) of 1997 provided an incentive for the pharmaceutical industry to complete pediatric studies of marketed drug products with patent life remaining while the FDA Final Rule of 1998 (effective April 1999) currently requires pharmaceutical companies to perform pediatric studies prior to filing of a new drug application (NDA) on new drugs that could benefit pediatric patients and/or are anticipated to be used in a substantial number (ie Ͼ50 000) of pediatric patients. These legislative changes produced a dramatic increase in the number (ie Ͼ400) of pediatric clinical trials conducted in the US (mostly pharmacokinetic), involving more than 50 000 children ranging in age from birth to adolescence and resulted in expanded pediatric labeling for more than 30 drug products.
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The Human Genome Project, initiated in 1990 with the goal of sequencing the entire complement of human genes by the year 2005, is the second development that is expected to impact the diagnosis and treatment of pediatric diseases. This three billion dollar public investment is expected to lead to decreased morbidity and mortality through the development of more effective strategies to diagnose, treat and prevent human disease. 2 Society has every right to expect that adults and children will be able to benefit equally from the promise of the genome era. In pediatrics, the newly acquired information has considerable potential to improve our understanding of: (1) genetic determinants of age-specific disease processes; (2) genetic and developmental factors that contribute to the increased susceptibility of children to certain drugrelated adverse events; and (3) genetic factors that influence interindividual variability in drug disposition and response across the entire pediatric age spectrum. Nevertheless, there are several factors unique to pediatrics that must be addressed before pharmacogenetic and pharmacogenomic strategies can be fully implemented in the context of pediatric disease. We will provide some perspectives on these issues as well as current ethical and methodological concerns that impact the translation of these strategies to pediatric clinical medicine.
Up to the present time, medical genetics has focused on unusual cases of Mendelian disorders, birth defect syndromes and chromosomal anomalies, generally within the setting of a pediatric tertiary medical center. With renewed interest in pediatric drug development and drug therapy over the past 5 years, the role of heredity can be expected to extend beyond diagnosis and surveillance to optimization of disease treatment-the ultimate goal of pediatric pharmacogenetics and pharmacogenomics. Defining the term 'pharmacogenomics' as the study of how interacting systems of genes determine drug responses 3 is particularly appealing to pediatric health and disease, since the concept of many genes acting in concert captures the essence of the developmental processes that characterize maturation from the time of birth through adulthood, while retaining a focus on the individual. In the context of drug therapy, the fetus is considered to be relatively deficient with respect to drug metabolizing enzyme activities and postnatally, the acquisition of functional activity appears to occur in isoform-specific patterns (reviewed in Leeder 4 ). Furthermore, it is not unreasonable to expect that receptor systems undergo maturational changes and neural networks become established as cognitive, verbal and social skills are acquired. Therefore, pediatric pharmacogenetics must identify the sources and consequences of inter-individual variability throughout development as they impact the disposition (ie pharmacokinetics) and action (ie pharmacodynamics) of drugs.
Applying pharmacogenomic data derived from studies conducted in adults or experimental systems of adult origin may have limited applicability to pediatric disease. Disease processes affecting newborn infants (eg patent ductus arteriosus) or diseases of childhood such as Kawasaki's disease have no close correlates in adults. Similarly, acute lymphoblastic anemia, Wilm's tumor and neuroblastoma are all encountered during childhood and rarely, if at all, in adults. Several diseases with complex etiologies such as asthma, autism, attention deficit and hyperactivity disorder, juvenile rheumatoid arthritis and type I diabetes mellitus have their origins during childhood and are associated with agerelated differences with respect to drug delivery, dosing and therapeutic response as compared to adults. Finally, certain forms of idiosyncratic toxicity such as Reye's syndrome associated with aspirin use, 5 valproate hepatotoxicity 6 and lamotrigineinduced cutaneous events 7 occur predominantly or at a considerably higher frequency in children implying that some determinants of susceptibility have a developmental component.
Genomic DNA obtained at any age or developmental stage can be used to identify specific single nucleotide polymorphisms (SNPs) or haplotypes of genes that contribute to the genetic liability (or genotype relative risk) for developing a specific complex disease as well as genes potentially predictive of an individual's response to pharmacotherapy. However, patterns of gene expression and the nature of the gene interactions that contribute to the pathogenesis of pediatric diseases (and thereby serve as potential targets for pharmacologic intervention) may only be discernable at specific critical points in the developmental continuum. For example, autism is one of a group of pervasive developmental disorders with lifelong consequences for affected individuals and their parents. The etiology of the disorder is poorly understood. It is thought to have genetic and environmental components and as recently suggested, may be a disease of early fetal development (reviewed in London 8 ). While any understanding of how interacting networks of genes are deranged in a complex disease clearly requires an understanding of the normal patterns of development, a major challenge for developmental disorders like autism will be to identify the critical period during development when deviations from normal patterns will be most
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Technological advances for studying gene expression (eg microarrays; proteomics tools such as two-dimensional electrophoresis coupled with mass spectrometry and isotope coded affinity tags, among others) will allow raw DNA sequence from the Human Genome Project ultimately to be converted to information related to the functional integration of biological systems. In particular, the new field of modular proteomics has considerable potential from a developmental perspective since it attempts to rationalize how proteins interact to form functional modules that then organize into network architectures of biological systems. 9 In this context, identification of appropriate tissues or model systems relevant to the target developmental stage represents a major challenge for pediatric pharmacogenomic endeavors. While tumor cells are readily accessible and provide exciting new possibilities for diagnosis and treatment using expression array technology, 10 appropriate tissue sources for microarray or proteomic investigations of neural development, the ontogeny of specific receptor and signal transduction systems or the ontogeny of drug metabolizing enzymes and transporters present more of a challenge for several ethical and logistical reasons. For example, 'fetal research' broadly refers to the use of fetal cells and tissues generally obtained from induced abortions for the purposes of studying various aspects of cell physiology and human development and as such, is a topic of considerable moral, ethical and political controversy. 11 Similarly, gene expression and proteomic investigations of human postnatal development require access to tissues of sufficient viability to allow isolation of intact mRNA and protein.
Transplant quality pediatric tissue is relatively rare and priority should be given to its use to save the life of a suitable recipient. Likewise, diseased organs/tissues removed from transplant recipients may not be suitable for investigational use in that they often reflect the effects of disease superimposed upon normal function. Tissue biopsies have been used for pharmacogenetic investigations in adults 12 but unless they are indicated for medical diagnosis or management, they are not easily defensible ethically in pediatric patients since greater than minimal risk is involved in obtaining them solely for research purposes. Continuous cell lines and primary cell cultures are potential alternatives but may not totally replicate and over time, may lose the specific developmental phenotype of interest. The use of 'humanized' transgenic animals holds some promise but thorough validation will be essential to ascertain their relevance to human development. Finally, the design of experimental systems to characterize the long-term consequences of pharmacologic intervention (eg possible longterm effects of psychotropics on the developing brain, an important concern in behavioral pediatrics 13 ) is a challenge that will require considerable creativity and resourcefulness to overcome.
The Ethical, Legal and Social Implications (ELSI) research program has been an integral component of the Human Genome Project since its inception. Ethical issues related to genetic testing in children have been addressed by several groups of practitioners including medical geneticists, 14 nurses 15 and pediatricians. 16 The common consensus from this program is: (1) that the primary justification for genetic testing in children and adolescents should produce a timely medical benefit to the child; (2) genetic testing should be preceded by informed parental consent and assent of older (ie = у7 years) children; and (3) that genetic testing for adult-onset conditions generally should be deferred until adulthood or until an adolescent has developed mature decision-making skills. Ethical issues considered for participation of children in clinical trials are most relevant to pharmacogenetic and pharmacogenomic strategies that may be enacted ultimately to impact the treatment of diseases/conditions such as asthma, epilepsy, cancer, transplant rejection, autoimmune diseases and inflammatory bowel disease, among others. Furthermore, the challenges (and potential rewards) are greatest for those conditions where the etiologies are poorly understood and as a consequence, the basis for rational pharmacotherapy is least evident. Consider the treatment of developmental and behavioral disorders such as autism, ADHD and obsessive-compulsive disorders in children where recent efforts provide an example of how clinical needs and challenges can be identified and prioritized, and strategies designed to meet those needs. The increasing use of psychotropic medications in preschool-aged children, 17 despite the absence of regulatory approval (ie approved pediatric labeling consequent to adequate testing to demonstrate efficacy and/or safety in this specific age group), prompted the National Institute of Mental Health and FDA to convene a workshop with representation from clinicians and researchers, family and patient advocates, industry, ethicists and professional societies specifically to examine the need for psychopharmacologic intervention for young children. 18 The outcome of this workshop was several specific recommendations relating to the need for new, targeted treatment interventions based on improved understanding of the pathogenesis of various disorders and the need for studies of efficacy and safety of drugs used to treat those disorders in children at all developmental stages. These studies should include the ontogeny of receptors and drug metabolizing enzymes as well as the ontogeny of drug effects on the developing brain to elucidate the short-and long-term consequences of treatment. 10 While these needs present tasks that are somewhat daunting to the field of pediatric psychopharmacology, they are equally applicable to the treatment of other pediatric disorders. Since this information is necessary for proper treatment of children, the research is justified provided that special attention is paid to identifying and minimizing potential risk, appropriate inforwww.nature.com/tpj med parental consent and child assent are obtained, specimens obtained for pharmacogenetic analysis (ie DNA) are used solely for the purposes described within a given research protocol and appropriate safeguards to protect the confidentiality of subject-derived information are enacted. 19, 20 The post-genomic era presents unprecedented opportunities to make significant contributions to clinical pediatrics through the purposeful and prudent incorporation of pharmacogenetic and/or pharmacogenomic 'tools' into clinical trials designed to examine drug disposition, action, efficacy and potentially, the epidemiology of therapeutic drug use (ie pharmacoepidemiology). Appropriate study design will be an increasingly important consideration as inevitable methodological difficulties are encountered. 21 For example, the number of children affected by a chronic disease such as arthritis is less than in adults and obtaining a sufficiently large study population to achieve statistical power represents a formidable challenge, especially when the frequency associated with a particular gene or allelic variant of interest is low. For diseases like asthma and ADHD where prevalence rates are much higher, the lack of objective diagnostic criteria poses a problem when establishing selection criteria for clinical trials and an obstacle for studies designed to establish roles for specific genes, SNPs or haplotypes in disease etiology or treatment outcome. For the revelations associated with this era of the human genome to be translated into discoveries with the potential to favorably impact the care and treatment of children, it will be incumbent upon society (ie both the scientific and lay public) to embrace the multiple opportunities afforded by new knowledge. This will require enhanced education of practitioners, parents and patients, and the development of new strategies that effectively integrate this 'new science' into paradigms of clinical research and patient care. The greatest obstacle to achieving the potential of pharmacogenomics and pharmacogenetics to improve clinical pediatrics will likely not result from a lack of personnel and fiscal resources to meet the challenges but rather, treating a facet of science that is common to all pediatric patients as uncommon, unattainable and/or of limited clinical utility. 
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